Department of Ophthalmology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Division of Vision Research, National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Department of Ophthalmology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Exp Eye Res. 2021 Jul;208:108623. doi: 10.1016/j.exer.2021.108623. Epub 2021 May 19.
The glutamate excitotoxicity has been suggested as a factor involved in the loss of retinal neuronal cells, including retinal ganglion cell (RGC), in various retinal degenerative diseases including ischemia-reperfusion injury, diabetic retinopathy, and glaucoma. Excitotoxic RGC death is caused not only by direct damage to RGCs but also by indirect damage due to the inflammation of retinal glial cells. Sphingosine 1-phosphate (S1P) and ceramides are bioactive sphingolipids which have been shown to possess important physiological roles in cellular survival and apoptosis, and the balance between S1P and ceramide, sphingolipid rheostat, has been suggested to be important for determining cellular fate. Therefore, we conducted the present study to clarify the neuroprotective role of sphingolipid rheostat in excitotoxic RGC death in vivo and in vitro. Acute RGC death was induced by intravitreal N-methyl-d-aspartate (NMDA) injection in the mouse. The mRNA expression of sphingosine kinase (SphK1/SphK2) was examined by quantitative real-time polymerase chain reaction (qRT-PCR). The expressions of SphK1/2, S1P, S1P-receptor (S1PR), glial fibrillary acidic protein (GFAP), Iba1, and CD31 were examined by immunostaining. Retinal sphingolipids and ceramides were quantified by liquid chromatography with tandem mass spectrometry. The neuroprotective effect of the sphingosine kinase inhibitor (SKI) on RGC death was assessed by RGC count and Terminal deoxynucleotidyl transferase dUTP nick-end labeling assay. Further, the in vitro effect of SKI was investigated using rat primary cultured RGCs and glial cells. In addition, MG5 cells and A1 cells, which were mouse microglia and astrocyte cell-line, were also used. The expression of cleaved-caspase-3, GFAP, and Iba1 in RGCs, primary glial cells, MG5 cells, and A1 cells was assessed by immunostaining. NMDA injection resulted in mRNA upregulation of SphK1; however, SphK2 was reduced in the mouse retina. SphKs, S1P, S1PR1, S1PR2, and GFAP expression increased in the early-stage NMDA group, whereas S1P and GFAP were higher in the late-stage NMDA + SKI group. In the NMDA group, S1P expression was lower whereas sphingosine, C20, C22, and C24 ceramides showed higher levels. The proportion of very-long-chain ceramide was elevated in the NMDA group but reduced in the NMDA + SKI group. SKI treatment significantly increased RGC survival in retinal wholemount analysis and decreased apoptosis in the ganglion cell layer and inner nuclear layer. In vitro, SKI suppressed excitotoxic RGC death, cleaved-caspase-3 expression, and activated glial cells. The findings in the present study provide the first evidence demonstrating the involvement of sphingolipid rheostat in the neuroprotection against excitotoxic RGC death. Therefore, regulation of sphingolipid rheostat might serve as a potential therapy for retinal degenerative disease.
谷氨酸兴奋性毒性已被认为是各种视网膜退行性疾病中视网膜神经元细胞(包括视网膜神经节细胞 [RGC])丧失的一个因素,这些疾病包括缺血再灌注损伤、糖尿病性视网膜病变和青光眼。兴奋性 RGC 死亡不仅是由 RGC 的直接损伤引起的,还可能是由视网膜神经胶质细胞炎症引起的间接损伤引起的。 1-磷酸鞘氨醇(S1P)和神经酰胺是生物活性神经鞘脂,它们在细胞存活和细胞凋亡中具有重要的生理作用,S1P 和神经酰胺之间的平衡,即神经鞘脂变阻器,对于确定细胞命运很重要。因此,我们进行了本研究以阐明体内和体外兴奋性 RGC 死亡中神经鞘脂变阻器的神经保护作用。通过向小鼠玻璃体腔内注射 N-甲基-D-天冬氨酸(NMDA)诱导急性 RGC 死亡。通过实时定量聚合酶链反应(qRT-PCR)检查神经鞘氨醇激酶(SphK1/SphK2)的 mRNA 表达。通过免疫染色检查 SphK1/2、S1P、S1P 受体(S1PR)、胶质纤维酸性蛋白(GFAP)、Iba1 和 CD31 的表达。通过液相色谱-串联质谱法定量测定视网膜神经鞘脂和神经酰胺。通过 RGC 计数和末端脱氧核苷酸转移酶 dUTP 缺口末端标记测定评估神经鞘氨醇激酶抑制剂(SKI)对 RGC 死亡的神经保护作用。进一步使用大鼠原代培养的 RGC 和神经胶质细胞研究 SKI 的体外作用。此外,还使用了 MG5 细胞和 A1 细胞,即小鼠小胶质细胞和星形胶质细胞系。通过免疫染色评估 RGC、原代神经胶质细胞、MG5 细胞和 A1 细胞中 cleaved-caspase-3、GFAP 和 Iba1 的表达。NMDA 注射导致 SphK1 的 mRNA 上调;然而,SphK2 在小鼠视网膜中减少。SphKs、S1P、S1PR1、S1PR2 和 GFAP 在早期 NMDA 组中表达增加,而 S1P 和 GFAP 在晚期 NMDA+SKI 组中更高。在 NMDA 组中,S1P 表达较低,而神经鞘氨醇、C20、C22 和 C24 神经酰胺水平较高。非常长链神经酰胺的比例在 NMDA 组中升高,但在 NMDA+SKI 组中降低。SKI 处理显著增加视网膜全层分析中的 RGC 存活,并减少神经节细胞层和内核层中的细胞凋亡。在体外,SKI 抑制兴奋性 RGC 死亡、cleaved-caspase-3 表达和激活神经胶质细胞。本研究的结果首次证明了神经鞘脂变阻器在对抗兴奋性 RGC 死亡的神经保护中的作用。因此,调节神经鞘脂变阻器可能成为治疗视网膜退行性疾病的一种有潜力的治疗方法。